Jazz Pharmaceuticals Completes EUSA Pharma Acquisition

18-Jun-2012 - Jazz Pharmaceuticals plc announced the closing of its acquisition of EUSA Pharma, a privately-held, specialty pharmaceutical company with a commercial presence in the U.S. and EU and a global distribution network. Following the closing, Jazz Pharmaceuticals now also markets a portfolio of ...

Siegfried (USA) Inc. and Jazz Pharmaceuticals sign Supply Agreement

31-May-2010 - Siegfried (USA) Inc announced that on April 1, 2010, a Supply Agreement with Jazz Pharmaceuticals Inc. was executed. Siegfried has the right to supply at least 60% of Jazz Pharmaceutical’s worldwide requirements of sodium oxybate, the active pharmaceutical ingredient in Xyrem® (sodium oxybate) ...

Jazz Pharmaceuticals and UCB announce Phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints

25-Jun-2009 - Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled ...

Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate in Fibromyalgia

Preliminary Top Line Results of Phase III Trial Show Significant Decreases in Pain and Fatigue and Improved Daily Function in Fibromyalgia Patients

24-Nov-2008 - Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the first of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its key endpoints, demonstrating that ...